Archives: News

From incubator to successful business… thank you AG-Bio Centre!

Our CEO, Francois-Thomas Michaud, has shared his thoughts on the importance of Business incubators and mentors for start-up companies with Nathalie Côté in the newspaper “La Presse” earlier this week. (LINK) Please find below the part about Feldan : Freely Translated from La Presse: They have developed their business with the help of incubators and […]

The First Allogeneic Regenerative Medicine in Japan

Mesoblast and Japanese company JCR Pharmaceuticals announced approval of Temcell (allogeneic mesenchymal stromal cell-based product) in pediatric acute GVHD in Japan. This is the first product to be approved under the Japanese “regenerative medicine law” that allows cell therapy treatment to go from a phase 1 directly to commercialization. Full News release Here About Mesoblast […]

CAR-T : the cancer treatment of the future?

The immunotherapies based on the use of Car-T cells (T-cells genetically modified to express a Chimeric Antigen Receptor targeted toward certain types of cancer cells) are seen as a potential therapeutic agent for the treatment of cancer. Certain companies decided to produce off-the-shelf allogeneic CAR-Ts (like Cellectis/Pfizer), while others chose an autologous platform where each […]

Epoxyeicosatrienoic acids : a novel class of stem cell engraftment enhancer

Researchers from Boston Children’s Hospital used a zebrafish model to test a new bone marrow transplant technique based on molecules called epoxyeicosatrienoic acids (EETs) that could prevent the body from rejecting bone marrow transplants. The team led by senior investigator Leonard Zon based its study on the use of an engineered transparent strain of zebrafish […]

A recent article from a UPenn team shows very promising result on the use of CAR T-cell therapy

Patients with multiply relapsed or refractory chronic lymphocytic leukemia (CLL) have a poor prognosis. CAR-modified T cells to treat 14 patients with relapsed and refractory CLL with 4 complete remissions (CR) and 4 partial remissions (PR) suggesting that disease eradication may be possible in some patients with advanced CLL using CAR T. Find abstract here

Intellia Therapeutics raises $70M in series B financing… One step closer to Gene Therapy

Intellia raises $70M in series B financing to pursue the development of Cas9-based gene therapies Intellia, one of the major genome editing players that are using the CRISPR\Cas9 system to modify genes, has received a series B financing of USD $70M (Link). This round has been led by OrbiMed and includes their partner Novartis as […]

Feldan has been selected to present at the Cold Spring Harbor meeting on Genome Engineering: The CRISPR/Cas Revolution

Feldan’s abstract “Innovative protein delivery system for cell therapy” has been selected to be presented at the Cold Spring Harbor meeting on Genome Engineering: The CRISPR/Cas Revolution on September 24th, 2015. About Cold Spring Harbor meeting on Genome Engineering: The CRISPR/Cas Revolution The specific goal for this meeting is to foster fruitful and creative interactions […]

Feldan : Finalist in The Redefining Early Stage Investments (RESI) Challenge!

Life Science Nation unveiled the finalists that were hand-picked to enter the RESI Boston Innovation Challenge: an exciting group of innovative life science companies in therapeutics, diagnostics, medical devices, and healthcare information technology (HC IT). Feldan is one of the companies selected to participate in The Redefining Early Stage Investments (RESI) Challenge in Boston! Dr. […]

Thank you Québec International !

Feldan would like to thank Québec International for the organization of the Québec Delegation at Bio Convention 2015. Article in French: La région de Québec représentée en force à BIO Philadelphie!

Feldan on the spotlight by the CCRM

Feldan is honored to be featured as the Industry Consortium Spotlight in The Niche, May News by the Centre for Commercialization of Regenerative Medicine.